에임드바이오

0009K0KOSDAQ

50.7 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment20.2 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 3.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AimedBio is a global biotech company specializing in the development of antibody-drug conjugate (ADC)-based anticancer therapeutics, leveraging patient-derived models and proprietary linker-payload technology. As a spin-off from Samsung Seoul Hospital, the company has achieved milestones through technology transfers and co-development agreements with global pharmaceutical firms since 2024.

Number of Employees

52people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

224.54Industry Average 15.000.0Point

15.0x industry avg (risky)

PBR

8.14Industry Average 1.200.0Point

6.8x industry avg (risky)

ROE

5.12Industry Average 8.002.5Point

Below industry avg

Debt Ratio

0.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Positive
“에임드바이오 투자 23배 회수”…민트벤처파트너스, 3개사 상장
mint벤처파트너스의 투자로 상장된 에임드바이오의 성공적인 시장 진입이 긍정적 영향을 미침.
Positive
민트벤처파트너스, 바이오 투자·창업 ‘투트랙’…1호 펀드 회수 성.....
민트벤처파트너스의 바이오 투자 및 창업 전략이 성공적으로 진행되어 에임드바이오를 포함한 여러 바이오 기업들의 성장이 기대되며, 이는 투자 회수율 향상과 산업 확장에 긍정적 영향을 미칠 것으로 보인다.
Neutral
“중국은 이제 경쟁 아닌 분석 대상”…글로벌 빅파마가 본 K-ADC 숙...
Global pharmaceutical giants view Korea's ADC technology development as a focus area rather than direct competition.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 24,250Won52-week high 72,50052-week low 17,900

1-month return2.0Point

1m -3.00% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인)2026-09-02
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인)2026-08-21
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인)2026-08-18
Neutral반기보고서 (2026.06)2026-08-12
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인 신청)2026-08-10